Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MBX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Canvuparatide | Hypoparathyroidism | Phase 3 · NCT07699471 | Recruiting |
| 200-1600 µg of MBX 2109 once-weekly by… | Hypoparathyroidism | Phase 2 · NCT06531941 | Active not recruiting |
| 400 µg of MBX 2109 once-weekly by subcutaneous… | Hypoparathyroidism | Phase 2 · NCT06531941 | Active not recruiting |
| MBX 1416 (INN imapextide) | Postbariatric Hypoglycemia | Phase 2 · NCT07029412 | Completed |
| MBX 2109 | Healthy | Phase 1 · NCT05158335 | Completed |
| MBX 4291 | Obesity | Phase 1 · NCT07142707 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MBX holds $482.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $28.7M/quarter from operations, an estimated runway of 50.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund 20 our operating expenses and capital expenditure requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MBX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 7,224,009 | 14.55% | 2026-09-30 |
| Patrick J Heron Director, 10% owner · +28,500 options |
Insider | 5,243,421 | 10.56% | 2026-08-06 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 4,977,523 | 10.02% | 2026-06-30 |
| Paradigm BioCapital Advisors LP | 5%+ holder (13G) | 3,772,885 | 7.60% | 2026-09-30 |
| Edward T. Mathers | 5%+ holder (13D) | 3,619,474 | 7.29% | 2025-11-06 |
| ORBIMED ADVISORS LLC | Institution (13G, 5%+) | 3,074,853 | 6.19% | 2026-08-06 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,628,181 | 5.29% | 2026-06-30 |
| P. Kent Hawryluk President & CEO, Director · +385,876 options |
Insider | 1,214,444 | 2.45% | 2026-05-06 |
| Steven L. Hoerter Chairman, President and CEO, Director · +499,500 options |
Insider | 98,045 | 0.20% | 2026-11-10 |
| John W Smither Chief Financial Officer · +130,000 options |
Insider | 28,000 | 0.06% | 2026-08-03 |
| Ora H. Pescovitz Director · +28,500 options |
Insider | 24,329 | 0.05% | 2026-06-04 |
| Richard Bartram Chief Financial Officer · +70,000 options |
Insider | 15,000 | 0.03% | 2026-02-02 |
Share count 49,656,265 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →